The QualityStocks Daily Newsletter for Thursday December 31st, 2009 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters


Greenbackers (QUIX)


Bloomfield Investment Club (RVGD)


Penny Stock MoneyTrain (KCMH)

The QualityStocks Daily

Aethlon Medical Inc. (AEMD)

OTC Picks, PennyOmega.com, DrStockPick.com, and Red Chip reported earlier on Aethlon Medical Inc. (AEMD), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 1991, Aethlon Medical Inc. creates diagnostic and therapeutic filtration devices to improve the health of individuals afflicted with infectious disease and cancer. They are the developer of the Hemopurifier®, a first-in-class medical device to treat infectious disease. The Hemopurifier® removes harmful substances from the blood. Aethlon Medical Inc. trades on the OTCBB. They have their corporate headquarters in San Diego, California.

The Hemopurifier® addresses the treatment of drug and vaccine resistant viruses. The Company's primary clinical and commercialization focus is to establish the Hemopurifier® as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens. The Company directs their international initiatives towards naturally evolving pandemic threats, and chronic infectious disease conditions. These include Hepatitis–C (HCV) and the Human Immunodeficiency Virus (HIV).

The Hemopurifier® assists the immune response in combating infectious disease through the selective adsorption of circulating viruses and immunosuppressive proteins. In the case of pandemic influenza, the Hemopurifier® has previously proven effective in capturing the reconstructed Spanish flu of 1918 virus (1918rv), and the H5N1 avian influenza virus (Bird Flu).

Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection. The Hemopurifier® also holds promise in cancer care. Research studies verify the Hemopurifier® effectively captures immunosuppressive exosomes secreted by tumors to kill-off immune cells.

The design of the multi–patented platform technology is for the single use removal of viral pathogens from blood. The cartridge mimics the natural response of clearing infectious viruses and related toxins prior to cell and organ infection. It is usable with portable pumps or within the established infrastructure of dialysis machines located in hospitals and clinics.

Aethlon Medical, Inc. announced in September that they initiated a relationship with Kentucky Bioprocessing LLC. This is to establish processes to support large-scale production of the active affinity agents immobilized within the Aethlon Hemopurifier®. Affinity agents allow the Hemopurifer® to capture selectively a broad-spectrum of viruses from blood and other fluids.

On December 15, 2009, Aethlon Medical, Inc. announced that Dr. Jeff Schorey and Dr. Wayne Comper joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Dr. Schorey and Dr. Comper are leading researchers in the exosome field. ESI, the wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier® is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The targeted removal of circulating exosomes to inhibit cancer related immune suppression could increase patient responsiveness to both immunotherapy and chemotherapy.

Aethlon Medical Inc. (AEMD) closed today at $0.30 down 1.64 percent. Volume was 233,022.

Cardo Medical, Inc. (CDOM)

Today we choose to highlight Cardo Medical, Inc. (CDOM), here at the QualityStocks Daily Newsletter.

Cardo Medical, Inc. is a company engaged in the development of orthopedic medical devices. The Company develops reconstructive orthopedic and spinal surgery products through advanced engineering. Their focus is on product development, marketing, and distribution within the U.S. market. Cardo Medical, Inc. trades on the OTCBB and they have their corporate headquarters in Beverly Hills, California. They also have a research and development office in Clifton, New Jersey.

Cardo Medical, Inc.'s commitment is to using their innovation to make complex and difficult surgical procedures easier, more reproducible, and safer, with predictable long-lasting outcomes.  The Company's engineering personnel collaborates closely with leading surgeons around the country to create products that reduce or eliminate joint pain and allow their patients to achieve more active lives. Cardo Medical works in small, focused development teams in concert with physicians to develop products from concept to launch rapidly. 

Their Orthopedics Division produces the Align 360® Unicompartmental Knee System, the Align 360® Patello-Femoral Knee System, the Align 360® Total Knee System, and the Press Fit Total Hip System. Their Spine Division produces the Cervical Plate System and the Pedicle Screw System. For Surgeon Resources the Company has their Align 360® Unicompartmental Knee System Technique. The Align 360 System is a minimally invasive technique designed to preserve bone stock, ensure highly reproducible bone cuts, and accurately align components under optimal tension.  The system is for cemented use only.

For Patient Resources, the Company offers their Align 360® Unicompartmental Knee Surgery option. This is partial knee replacement surgery (Unicompartmental Knee Replacement). Knee arthritis often affects only one side of a knee. The remaining parts of the knee can be healthy. A surgeon can use the Align 360® Unicompartmental Knee System, which resurfaces only the damaged part, saving the rest of the knee with its healthy cartilage. The implant can restore function to a knee and relieve pain. Often this procedure is done in lieu of a full knee replacement.

In October, Cardo Medical announced that they acquired substantially all of the assets of Vertebron Inc., a spinal implant device company located in Stratford, Connecticut, for $1.3 million in cash. Vertebron designs, develops, manufactures, and sells spinal implant products focused on fusion technology for the lumbar and cervical spine as well as motion preservation technologies. Cardo Medical will retain 100 percent ownership of all Vertebron's implant technologies for spinal surgery. They have also acquired all intellectual property rights owned by Vertebron. This includes more than 20 U.S. issued patents and patent applications.

Cardo Medical, Inc. (CDOM) closed Thursday's session at $0.8510 on no volume.

Clear One Health Plans, Inc. (CCHN)

Stock Guru and SmallCap Voice reported earlier on Clear One Health Plans, Inc. (CCHN), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Clear One Health Plans, Inc. operates as an insurance company that provides members with access to physicians and health insurance coverage. Trading on the OTCBB, the Company offers health insurance, including individual plans, Medicare Advantage plans, group plans, and administrative services. This is to individuals and businesses throughout Oregon and Montana. Clear One Health Plans, Inc. has their headquarters in Bend, Oregon.

The Company has continuously developed affordable plans to meet the needs of customers, providers, brokers, and consumers. They are the first managed care plan nationwide to be owned and operated by physicians and hospitals. The Company dedicates their efforts to the development of community-based health insurance plans by using local providers and quality clinical evaluations as a basis for decision-making.

Clear One Health Plans has more than 145 employees and they serve 40,000 residents throughout Oregon and Montana. They do this while providing access to high quality care from most of the physicians and hospitals in their Oregon and Montana markets. Their members also have nation-wide access to quality hospitals and physicians. In addition, they have the highest level of benefits for covered services at home, on vacation, traveling on business, or away at school.

Yesterday, Clear One Health Plans, Inc. reported that they will be merging with PacificSource Health Plans in a deal valued at $46 million. Shareholders of Clear One will get $26 per share in cash, a premium of 167 percent to the Tuesday, December 29, 2009 closing price of $9.75. Upon the closing of this deal, Clear One Health Plans, Inc. will be a wholly owned subsidiary of PacificSource.

The Board of Directors of both companies unanimously approved the transaction. Clear One entered into the merger agreement following unanimous recommendation by a special committee comprised of independent directors. The parties currently anticipate consummating the transaction during the latter part of the first calendar quarter of 2010.

Patricia Gibford, President and Chief Executive Officer of Clear One, said, "This is an excellent opportunity for Clear One members, providers, and employees to become part of a leading organization. We have tremendous respect for PacificSource and their management, and look forward to becoming part of the PacificSource team."

Clear One Health Plans, Inc. (CCHN) closed today at $24.50 up 151.28 percent. Volume was 51,785.

Emisphere Technologies, Inc. (EMIS)

Greenbackers reported this month on Emisphere Technologies, Inc. (EMIS), SmallCap Voice, M2 Communications, and OTC Picks did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Emisphere is a biopharmaceutical company that focuses on the unique and improved delivery of therapeutic molecules or nutritional supplements using their proprietary Eligen® Technology. The Eligen® Technology can undergo application to the oral route of administration as well as other delivery pathways. These include buccal, rectal, inhalation, intra-vaginal, or transdermal. Emisphere Technologies, Inc. trades on the OTC Bulletin board and they have their headquarters in Cedar Knolls, New Jersey.

The Company's core business strategy is to use their proprietary Eligen® Technology to develop novel oral forms of injectable drugs or poorly absorbed compounds. Eligen® Technology improves the body's ability to absorb select molecules. Their carriers provide a demonstrated safe method of chaperoning molecules without affecting their biological benefit. Many of these molecules currently deliver via injection, such as salmon calcitonin. In certain cases, their benefits are limited. This is due to poor bioavailability, slow onset of action, or variable absorption, such as Vitamin B12.

Emisphere Technologies, Inc.'s pipeline includes product candidates that have reached clinical development. They also include a variety of preclinical research and development programs. They are carrying out these programs both in collaboration with pharmaceutical and biotechnology companies and independently. Marquee products in the Company's pipeline include an improved formulation of oral Vitamin B12, oral calcitonin for osteoarthritis and osteoporosis (in Phase III development with Novartis), and oral GLP-1 and GLP-1 analogs for Type 2 diabetes.

On Monday, December 21, 2009, Emisphere Technologies announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

Oral salmon calcitonin uses the proprietary absorption enhancing Eligen® Drug Delivery Technology. It is undergoing study in osteoarthritis and osteoporosis by Novartis Pharma AG and Nordic Bioscience. Scientists from Nordic Bioscience were involved in the preparation of the meta-analysis.

"An ideal treatment with an optimal efficacy, safety and convenience profile is not available for the musculoskeletal pain associated with such conditions as osteoporosis and osteoarthritis. This review of the literature highlights the clear unmet medical need that could be addressed by Emisphere's oral salmon calcitonin product," said Michael V. Novinski, President and Chief Executive Officer, Emisphere Technologies.

Emisphere Technologies, Inc. (EMIS) closed Thursday's session at $1.06 up 7.07 percent. Volume was 551,118.

MedaSorb Technologies Corporation (MSBT)

PennyOmega.com, Hyper Growth Stock, Penny Invest, and StockEgg.com reported earlier on MedaSorb Technologies Corporation (MSBT), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

MedaSorb Technologies Corporation, and their operating subsidiary CytoSorbents, Inc., is a therapeutic device company. They are engaged in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood-purification device called CytoSorb™. The Company's management team includes individuals with expertise in the fields of polymer research and development, medical device development, business management and entrepreneurship, blood purification, high-volume medical device manufacturing, and corporate finance. MedaSorb Technologies Corporation became public June 30, 2006 through a merger transaction with Gilder Enterprises. They list on the OTC Bulletin Board and they have their headquarters in Monmouth Junction, New Jersey.

MedaSorb, operating exclusively through Cytosorbents Inc., focuses on the development of products to support healthcare professionals in the treatment of complex medical conditions. CytoSorbents Inc. has developed a new adsorbent platform technology. This is for removal of toxins from blood and physiologic fluids.

The Company's products consist of porous, adsorbent polymer beads. These beads target molecules up to 50,000 Daltons, which are associated with sepsis. The belief is that these cytokines are largely untouched by current blood purification techniques, including state of the art dialysis technology. CytoSorbents' near term focus is achieving regulatory approval of CytoSorb™. They expect to use this for the treatment of sepsis, cardiopulmonary bypass surgery, organ donation and drug overdoses. These all have a common theme, which is blood borne toxins. 

Their first product will be a medical device containing their proprietary polymer beads. Their adsorbent polymer bead technology has a porous surface, and uses size-selectivity for filtering toxins from blood and physiologic fluids. The polymer beads are a touch larger than a grain of salt and are highly compatible with blood.

MedaSorb Technologies Corporation and their wholly owned subsidiary CytoSorbents, Inc., announced in October that they raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008.  The funds are helping the Company finance their ongoing European Sepsis Trial and the CE Mark application process.

MedaSorb Technologies Corporation is currently conducting their European Sepsis Trial. This trial is a multi-center, randomized, controlled clinical trial using their flagship CytoSorb™ device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. The Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union, pending a successful trial.

MedaSorb Technologies Corporation (MSBT) closed Thursday's trading at $0.19 up 5.56 percent. Volume was 1,172,823.

Primus Telecommunications Group, Incorporated (PMUG)

Today we highlight Primus Telecommunications Group, Incorporated (PMUG), here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, Primus Telecommunications Group, Incorporated is an integrated facilities-based telecommunications services provider. The Company offers international and domestic voice, voice-over-Internet protocol (VOIP), Internet, wireless, data, and hosting services. They offer these to business and residential retail customers and other carriers located in the United States, Canada, Australia, the United Kingdom, and Western Europe. Founded in 1994, Primus Telecommunications Group, Incorporated has their headquarters in McLean, Virginia.

With annualized revenue of approximately $800 million, Primus provides services over their worldwide network of owned and leased transmission facilities. These include approximately 500 points-of-presence (POPs) globally, ownership interests in undersea fiber optic cable systems, 18 carrier-grade international gateway and domestic switches, and a variety of operating relationships that allow the Company to deliver traffic worldwide.

The Company delivers solutions for more than 2.4 million consumers. They take advantage of global telecommunications deregulation. This allows Primus to bring their clients facilities-based networks and facilities-based datacenters for a sophisticated line of services to manage their complete E-Business and data communication needs.

Primus Voice Services offers a set of residential and business voice services. These include domestic and international long distance, international toll-free service, calling cards, and prepaid long distance.  Primus E-Business solutions through their Primus suite integrates global data and Internet services, which ride on Primus' facilities-based assets. Primus suite services include ASP (Application Service Provider) Services, dedicated T-1 and Dial-up Internet Access, DSL (Digital Subscriber Line), and Global IP Roaming.

Primus Telecommunications Group, Incorporated announced in October the opening of their Chicago office. This office is as part of their strategy to gain market share in the business customer segment. The Chicago office is focusing on providing fully managed hosted PBX (Private Branch Exchange) services to small and medium-sized businesses in the Midwest region.

Last month, Primus Telecommunications Group, Incorporated announced results for the third quarter of 2009. Net revenue was $207.9 million; Adjusted EBITDA was $21.0 million; and Free Cash Flow was $9.1 million. The Company had a $41.9 Million Cash Balance at September 30, 2009.

Primus Telecommunications Group, Incorporated (PMUG) closed Thursday's session at $5.75 down 0.86 percent. Volume was 9,500.

Rahaxi, Inc. (RHXI)

Today we highlight Rahaxi, Inc. (RHXI), here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, Rahaxi, Inc. is an international payment processing and technology company. They operate a BASE24 credit card processing platform, which currently processes approximately two million card payments per month. This is for an established client base including companies such as Stockmann, Global Refund, and Finnish State Rail (VR). Rahaxi, Inc. has their corporate headquarters in Santo Domingo, Dominican Republic. They also have offices in Dublin, Ireland, and Helsinki, Finland.

Rahaxi, Inc. provides mission-critical solutions to the financial industry worldwide. Working with merchants and acquirers in more than twenty countries, their product suite has helped their partners to focus on their core competencies.  The Company's partners are market leaders in their respective industries. Along with the above-mentioned companies, their partners also include IKEA and Finnair.

Rahaxi's subsidiaries, Rahaxi Processing Oy, Finland, FreeStar Technologies Ireland, Ltd., and FreeStar Dominicana S.A. Dominican Republic, continue to develop and implement products and solutions that enhance the service level that their partners can offer their customers. Rahaxi, Inc. also focuses on exploiting a first-to-market advantage of their Enhanced Transactional Secure Software (ETSS). This is a software package that helps consumers to consummate e-commerce transactions with a high level of security using credit, debit, ATM (with PIN) or smart cards.

Rahaxi, Inc.'s solution greatly reduces chargebacks. This allows companies to forecast sales figures more accurately. Rahaxi, Inc.'s technology also assists individual consumers to safeguard their financial privacy and protect their credit information during transactions with online merchants.

Rahaxi, Inc. announced in October that their subsidiary Rahaxi Processing Oy and jeweler chain giant Kultajousi Oy entered into an agreement to supply their OTI (Open Terminal Interface) solution to over 60 different stores in 27 different cities in Finland. Golden Heights Group owns Kultajousi.

On December 9, 2009, Rahaxi, Inc. reported that they're set to offer their already certified platform for CUP debit card acceptance to banks, third party processors, and independent sales organizations. The design of this move is to expand their CUP card acceptance service offering all over Europe and beyond. The Company expects to derive additional revenue from the license and transaction fees they will generate from usage of their platform.

Rahaxi, Inc. (RHXI) closed today at $0.02 up 10.50 percent. Volume was 839,281.

Mogul Energy International Inc. (MGUY)

We are highlighting Mogul Energy International Inc. (MGUY), here at the QualityStocks Daily Newsletter.

Mogul Energy International, Inc. is an international oil and gas exploration company. They have a professional management team with proven records of accomplishment in oil and gas exploration and development. The establishment of the Company was to build an international oil and gas exploration enterprise with a focus in Canadian and International Concessions. Trading on the OTCBB, Mogul Energy International Inc. has their headquarters in Seattle, Washington. They also have an office in Toronto, Ontario.

The Company's mission is to explore and develop highly prospective lands adjacent to producing oil fields in the world's most viable and qualified properties. They have entered into an agreement with Excelaron LLC. With the agreement, Mogul Energy has acquired a 40 percent membership interest in Excelaron LLC, a California based company. Excelaron LLC is in the process of developing oil leases that Excelaron has entered into, located in California.

In addition, Mogul Energy International Inc. has a 100 percent working interest in the Fairlight Project. This project consists of oil and gas leases in the Fairlight Area of South East Saskatchewan, Canada. The project is on approximately 9,300 acres of land. Chapman Petroleum Engineering, on October 1, 2007, completed their third-party analysis report on this property and identified three prospects detailed in their report.

Mogul Energy's Huasna Field in California is approximately 12 miles east of the City of Arroyo Grande. The expected product from the successful operation is heavy oil with the additional potential for a light oil play. The exploitation of the oil gravity in the Monterey shale accumulation will be facilitated by application of an enhanced recovery system by hot water injection.

In Canada, Mogul has placed a particular emphasis on exploration of the Bakken Formation in the aforementioned Fairlight area. The Fairlight area of Southeastern Saskatchewan is highly prospective for light oil. The drill program for Mogul's South East Saskatchewan properties will primarily test the potential of the three shallow reservoirs of Birdbear, Lodgepole, and Bakken. The Fairlight area of South East Saskatchewan also goes by the name Freehold Properties. Mogul is also the sole operator of the Freehold Properties.

Excelaron LLC is Mogul Energy's partner in the exploration and development of the California leases located in San Luis Obispo, California. The team has been working on the community and planned construction to complete successfully the development plans of the wells outlined in the California plan. Excelaron LLC is partially owned and managed by Australian Oil Company Limited.

Mogul Energy International Inc. (MGUY) closed today's trading session at $0.0670 up 21.82 percent. Volume was 5,000.

The QualityStocks Company Corner

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH) Today, General Environmental Management Inc. closed trading at $0.27, which was up 17.39 percent. Their volume today was 14,000 shares.

Consorteum Holdings, Inc. (CSRH) is focused on providing financial services, electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. The company's services provide customized, innovative technology solutions that create, augment and enhance their clients' existing financial, payment and transactional processing systems.

The company offers clients a long-term strategic plan utilizing the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create exceptionally customized programs. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new revenues.

Consorteum's strategy is to capitalize on the global opportunities within the growing financial services, payment and transaction processing marketplace. The utilized business model generates revenues on every transaction touched, thus providing long-term, sustainable income. The company has strategically designed its business initiatives to create significant repetitive transactions on an ongoing basis. Additional company revenues are generated from consulting services, project minimums and management fees.

The company is jointly led by CEO Craig Fielding and President & COO Quent Rickerby. Mr. Fielding brings a wealth of expertise in the payments industry, in both local and international payment processing, along with HR-specific business management expertise, leadership, customer development and acquisition skills. Mr. Rickerby brings over two decades of business management, international and domestic sales experience, new company start-up, payment processing, project management, business development, negotiations, relationship management and strategic company direction.Disclaimer

Consorteum Holdings, Inc. Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Inc. Provides Investor Update on Initial North American Contracted Projects

Consorteum Holdings Inc. Launches Alternative Mail-In Rebate Program for Manufacturers and Retailers

Consorteum Holdings Inc. Provides Manufacturer and Retailer Solutions in North America and Europe

General Environmental Management (GEVI)

The QualityStocks Daily Newsletter would like to spotlight General Environmental Management Inc. (GEVI) Today, General Environmental Management Inc. closed trading at $0.27, which was up 17.39 percent. Their volume today was 14,000 shares.

General Environmental Management Inc. (GEVI) is in the process of shifting its business focus from hazardous waste field services to the fast growing water treatment and waste-to-energy markets. Since its inception in 2002, the Company has grown at a compounded annual rate of 48% to generate annual revenues of $37M from only $2.3M.

This strategic decision was made after an all inclusive analysis of GEVI's opportunity in the environmental management business. Although the company could work through the current economic downturn and build revenue in its field services business, they believe that shareholders will be rewarded by moving the company into the higher margin, faster growing business segments.

Within the U.S. alone, the water industry is a $120 Billion market that is expected to grow at 6-7% over the next year. On a global basis, the industry size exceeds $400 billion annually and increasing with the demands of a growing world population. The global waste-to-energy market, on the other hand, is a $19.9 billion market with expected CAGR of 6.7% over the next five years.

In order to ensure every advantageous acquisition opportunity is properly evaluated, GEVI has retained the services of General Pacific Partners (GPP). With a very selective and calculated acquisition strategy in place, GEVI is poised for continued success. Disclaimer

General Environmental Management Inc. Blog

General Environmental Management Inc. News:

General Environmental Management Announces Release of Quarterly Report

Reminder Notice: General Environmental Management Investor Conference Call 12/2/09 at 4:30pm EST

General Environmental Management Announces Completion of Acquisition of Santa Clara Waste Water

NetSol Technologies, Inc. (NTWK)

The QualityStocks Daily Newsletter would like to spotlight NetSol Technologies, Inc. (NTWK). Today, NetSol Technologies, Inc. closed trading at $1.07, which was up 5.94 percent. Their volume today was 311,033 shares.  

NetSol Technologies, Inc. (NTWK), a worldwide provider of global business services and enterprise application solutions, leverages its BestShoring(TM) practices and highly experienced resources to deliver high-quality, cost-effective solutions. The

ir suite of products and services include credit and finance portfolio management systems, hospital/healthcare information management systems (HIMS), SAP consulting and services, custom development, systems integration, and technical services.

NetSol’s commitment to quality is demonstrated by its achievement of the ISO 9001, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by less than 100 companies worldwide. These distinctions are a result of adhering to rigorous quality standards, resulting in the delivery of solutions that are secure, reliable, properly planned, and meticulously executed.

Serving the global financial, healthcare, insurance, energy, and technology markets, NetSol has operations, offices, and joint ventures in Adelaide, Bangkok, Beijing, Lahore, London, Riyadh, San Francisco, and San Pedro Sula. NetSol Technologies' clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies.

NetSol Technologies, Inc. (NTWK), is well positioned with its core product offerings as it continues to expand into new international market opportunities. Looking forward, the company is very optimistic of its short-term and long-term outlook as it sees strong growth in Asia Pacific as well as the South East Asian markets, while also envisioning unlimited potential for its niche solutions and services in the Americas. Disclaimer

NetSol Technologies, Inc. Blog

NetSol Technologies, Inc. News:

NetSol Technologies Wins a Major Information Security Contract in the Mobile Telecommunications Sector

NetSol Technologies Issues Financial Guidance for Fiscal Year 2010, Period Ending June 30, 2010

NetSol Technologies to Present at Equities Winter Discovery Day Conference in New York on December 11, 2009

Kraig Biocraft Laboratories, Inc. (KBLB)

The QualityStocks Daily Newsletter would like to spotlight Kraig Biocraft Laboratories, Inc. (KBLB) Today, Kraig Biocraft Laboratories, Inc. closed trading at $0.0126, for no change. Their volume today was 170,000 shares.

Kraig Biocraft Laboratories, Inc. (KBLB) a biotechnology company, has their focus on developing high performance polymers and technical fibers. The company is utilizing their proprietary genetic engineering technology to develop and produce polymers and protein-based materials, including Spider silk, which may have numerous commercial and consumer applications.

Kraig Biocraft Laboratories, Inc. (KBLB) is working with university scientists and laboratories to create these new polymers that have potentially broad applications in the multi-billion dollar marketplace for high performance polymers. The company sponsors and collaborates on research projects within university genetic engineering laboratories as a means of utilizing the greatest minds in their field.

Spider Silk is one of the strongest fibers produced in nature. The spider's repelling silk is of particular commercial interest since it is both extremely strong and extremely flexible. Although exciting commercial opportunities exist for the natural polymer, there is no known way to produce the fibers in commercial quantity. KraigLabs, in cooperation with two leading universities, has acquired proprietary genetic engineering technology to unlock the mystery.

CEO Kim Thompson leads the company with formal education in the fields of economics and law. With interest in genetic engineering dating back to the 1970s, Mr. Thompson has invented a pending provisional patent application for a number of organic polymers. This patent application has been assigned to benefit Kraig Biocraft and is a central part of the company's efforts in bringing those inventions to the market. Disclaimer

Kraig Biocraft Laboratories, Inc. Blog

News for Kraig Biocraft Laboratories Inc.

The New Age of Partnerships

Kraig Biocraft Laboratories, Inc. Greatly Exceeds Its Performance Goals

SectorWatch.biz: Paving the Way for Spider Silk

NetSol Technologies, Inc. (NTWK) Sets International Standard for Leasing and Finance Solutions

NetSol Technologies, Inc., the established provider of business services and enterprise software solutions to a growing global market, developed the NetSol Financial Suite (NFS) as a framework for robust and highly customized solutions that offer tight integration with existing systems across environments with multiple assets and languages.

One major, fully-integrated component of the NFS is the industry-renowned LeaseSoft, NetSol’s suite of end-to-end leasing and finance software solutions. Developed for finance and lending industries around the globe, NetSol Technologies Limited has created a unique suite of Enterprise IT Managed solutions based on the proven LeaseSoft technology.

LeaseSoft Asset is a specialized finance system, designed from the ground up to be a web-enabled package that harnesses the underlying technology that has made the NFS so successful.
The software is modular and therefore highly scalable while being robust enough to make it a clear industry leader in asset finance systems around the world. With an emphasis on accuracy and flexibility, LeaseSoft Asset was developed for tight integration with LeaseSoft Portal and Document Manager.

With the capacity to leverage additional applications for greater overall profitability in a way that allows for an increased variety of potential uses, LeaseSoft Asset is able to meet the demands of a growing and changing market on a stand-alone basis while interfacing seamlessly with external systems.

LeaseSoft Asset supports all the basic needs of captive finance, vendor and banking companies. Suitable for a wide range of installment credit lenders, including high volume lenders, LeaseSoft Asset was tailor-made for leasing, operating leasing, hire purchase, motor, finance and corporate products.

LeaseSoft Evolve was created with smaller finance companies in mind, especially those doing installment lending management, as a leasing loan administration toolkit which comes pre-configured, thus allowing rapid implementation into a company’s workflow.

Evolve is designed to be a cost-effective solution for business ranging from start-ups to established operations looking to streamline their process, including businesses with component broker and in-house-based finance. Because LeaseSoft Evolve allows for the easy creation and management of contracts throughout their life-cycle, and does so with a simple and solitary database structure, service is optimized and risk is reduced while allowing personnel to focus on other tasks.

Designed to be a comprehensive and powerful finance contract management system, this largely automated and web-enabled environment allows for easy management of multiple simultaneous contracts with little to no human intervention.

The ability to service every aspect of its targeted solution set, including uploading and cross checking, lookups, payouts, underwriting and even direct debiting in an automated and hands-free manner, leaves only tasks such as the amendment or early settlement of contracts to the end-user, and even in such cases allows for simple outsourcing to third party agencies.

National Holdings Corp. (NHLD) Reports Record Revenues for 2009

Operating through its wholly-owned subsidiaries, National Holdings Corp., a full service investment banking company, yesterday reported record revenues for the company’s fiscal year ending September 30, 2009.

National Holdings realized a net loss of $6.79 million on revenues of $116.59 million, compared to last year’s loss of $21.36 million on revenues of $82.14 million. After providing for cumulative dividends, the company had a basic and diluted net loss per share of $0.41; in 2008, the basic and diluted net loss per share was valued at $2.02. Additionally, outstanding basic and diluted shares were 16,760,243 for the fiscal year ending September 30, 2009, while last year’s were 10,579,778.

Mark Goldwasser, CEO of National Holdings, commented, “The market volatility over the past fiscal year resulted in a challenging business setting, yet despite this difficult environment, we look forward to the future with a high level of optimism in light of our record revenues in excess of $116 million and adjusted EBITDA loss of ($1.28 million) for the fiscal year ended September 30, 2009. We believe that we are well positioned to achieve success should the markets continue to stabilize and improve.”

National Holdings’ President Leonard J. Sokolow added, “We have begun to see the benefits of diversification of our revenue base as well as investment into our infrastructure, investment banking and research capabilities with a view towards improving our profit margins. In light of these trends, we expect that our first quarter ending December 31, 2009 will show revenues of approximately $28.0 million and positive adjusted EBITDA.”

Simulated Environment Concepts, Inc. (SMEV) Signs Multi-Million Dollar International Distribution Agreement

Simulated Environment Concepts, Inc., makers of the high pressurized dry water massage and relaxation station SpaCapsule, was pleased to announce today that it has completed negotiations with the French company Zen & O. As a result of their negotiations, Simulated Environment Concepts secured a multi-million dollar deal to manufacture 250 SpaCapsules over the next four years. This agreement expands the company’s reach into central Europe.

“This is a significant, multimillion dollar contract for a minimum of 250 units,” stated Dr. Ella Frenkel, President and CEO of Simulated Environment Concepts. “It’s a clear indication that the personal wellness industry continues to thrive globally even through the current recession. We began to work on the contract in May of 2009 and after mutual visits between France and the USA we signed the contract and secured a payment this December for the first order of the New Year.”
Zen & O is a French company in the forefront of fitness. With various subsidiaries and partnerships, the company is involved in fitness and retail operations, providing on-the-go massage at retail locations throughout Europe.

“SpaCapsule will become a centerpiece of our ‘Lady Fitness’ operations,” said Harve Rivoal, Lady Fitness Centers, CEO, who operates 54 centers in France, Belgium, Luxembourg, Switzerland, and Spain. “Our customers wish for a total fitness experience — from workout to massage to cellulite treatments. We love the fact that SpaCapsule can offer an excellent range of services without adding additional personnel. Because the SpaCapsule does not require attendants, we anticipate increased revenues with reduction in payroll and associated costs.”

Retail operations will use the SpaCapsule to provide massage and cellulite treatment to shoppers in malls. Stephane Tournier, a manager at Aquadetente, the mall operations arm of Zen & O, commented, “The uniqueness of SpaCapsule is that an individual can have a dry aqua massage without undressing or getting wet. While in the SpaCapsule the customer is watching video, listening to music, and inhaling scented oxygen. If the customer wants, he or she can even use their own iPod. We are gearing to open many more locations throughout France and Spain. For the past four years we used a competing technology made by AquaMassage to test out and prove the concept. However now, we will use SpaCapsule exclusively because of its technological and aesthetic superiority. This is indeed a beautiful machine that utilizes the latest computer technology for accounting and usage tracking”

“This contract is a significant milestone for us,” stated Dr. Spivak, Managing Partner at Simulated Environment Concepts who was extensively involved in the negotiation and execution of the agreement. “This commitment will provide revenue stability for many years to come. In addition, the European retail locations will serve as mini ‘showrooms’ for any new customers throughout Europe and undoubtedly generate more sales. We are very excited.”

Dr. Spivak added, “This is an exciting finale to 2009. We are currently assembling the first order of the New Year and anticipate on-time delivery. We’re also planning strategy to support and increase our new affiliate’s sales with new marketing initiatives and incentives.”

China Yongxin Pharmaceuticals, Inc. (CYXN) Announces 2009 Projected Financials

China Yongxin Pharmaceuticals Inc., a leading producer and distributor of Chinese traditional medicines, pharmaceuticals, health food, cosmetics, and related products, today announced projected financial results for the year ending December 31, 2009.

Although net income for the year is projected to increase 35% to $5.4 million, over 2008, a shift in sales strategy has led to a reduction in projected revenues. 2009 revenues are now projected to be $46.1 million, down 22% from $59.1 million in 2008. The company’s sales strategy is being shifted from wholesale to the retail and medical facilities sector due to the uncertain direction of the National Medical Policy. Revenues from the company’s retail drug stores increased by 30% over 2008, but this was not sufficient to overcome the impact of the decrease in wholesale operations. The increase in net income is due primarily to higher margin retail and medical facilities sales, the new area of focus.

Company chairman and CEO, Mr. Yongxin Liu, commented that wholesale business was impacted by customers waiting for specifics on the new healthcare reform plan. “However, on August 18th, the Chinese government issued China’s Essential Drug List (EDL) which included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. We are pleased that China Yongxin is a retailer or distributor of 295 of the products on that list. We are further encouraged by the increasing momentum toward healthcare reform and the government’s efforts to boost domestic spending. During 2009, we also added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province and we expect this to drive market share gains and growth during the coming year.”

China Yongxin Pharmaceuticals was founded in 1993, but didn’t begin retail operations until 2004. In 2005, it gained franchise rights from one of the world’s largest drug chains for China’s Jilin Province. By the end of 2007, it had become one of the fastest growing drug retailers in China through its chain of 93 drug outlets, as well as wholesale distribution and manufacturing operations in Northeastern China.


Sponsors of the Day


The QualityStocks Public Company Sponsor News



About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336